The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 28, 2021

Filed:

May. 30, 2018
Applicants:

Immunolight, Llc, Detroit, MI (US);

Duke University, Durham, NC (US);

Inventors:

Frederic A. Bourke, Jr., Aspen, CO (US);

Mark Dewhirst, Chapel Hill, NC (US);

Neil Spector, Durham, NC (US);

Paul Yoon, Durham, NC (US);

Justus Adamson, Durham, NC (US);

David Alcorta, Durham, NC (US);

Kim Lyerly, Durham, NC (US);

Leihua Liu, Durham, NC (US);

Takuya Osada, Durham, NC (US);

Mark Oldham, Durham, NC (US);

Zakaryae Fathi, Raleigh, NC (US);

Wayne F. Beyer, Bahama, NC (US);

Harold Walder, Belville, NC (US);

Assignees:

IMMUNOLIGHT, LLC, Detroit, MI (US);

DUKE UNIVERSITY, Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 41/00 (2020.01); A61K 31/37 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61N 5/06 (2006.01); A61N 5/10 (2006.01); A61K 31/409 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 41/0042 (2013.01); A61K 9/0009 (2013.01); A61K 31/37 (2013.01); A61K 31/409 (2013.01); A61K 41/0038 (2013.01); A61K 41/0066 (2013.01); A61K 45/06 (2013.01); A61N 5/062 (2013.01); A61N 5/10 (2013.01); A61K 2300/00 (2013.01); A61N 2005/0661 (2013.01); A61P 35/00 (2018.01);
Abstract

A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.


Find Patent Forward Citations

Loading…